FDA denies acne petition
This article was originally published in The Rose Sheet
Executive Summary
D'Arcy Skincare petition requesting 10% sulfur and 2% salicylic acid combination be recognized as safe and effective under the OTC topical acne drug products monograph is denied by FDA. Agency says it is "unaware of any clinical studies demonstrating that both sulfur and salicylic acid contribute to the overall effectiveness of the combination" and notes D'Arcy did not submit effectiveness data to support its position. Although 3%-10% sulfur and .5%-2% salicylic acid are permitted under the monograph, they are not allowed at those levels in combination. D'Arcy includes 2% salicylic acid and 10% sulfur in combination in its Drying Lotion acne treatment and argued it has seen no adverse effects during more than 20 years of marketing the product. The company also submitted repeat insult patch test to FDA to support safety and consumer testimonials to prove efficacy (1"The Rose Sheet" July 19, 2004, p. 8)...
You may also be interested in...
Acne Active Ingredient Combination Urged In Citizen Petition To FDA
FDA should permit the use of 2% salicylic acid and 10% sulfur as combination active ingredients in the final monograph for topical acne drug products, D'Arcy Revolutionary Skincare states in a 1citizen petition to FDA
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.